scholarly journals Modeling Virologic Response in HIV-1 Infected Patients to Assess Medication Adherence

10.5772/33471 ◽  
2012 ◽  
Author(s):  
Yangxin Huang
Keyword(s):  
Medication Adherence ◽  
Virologic Response ◽  
Hiv 1

scholarly journals Pharmacotherapy of HIV: A Focus on Atazanavir/Ritonavir a Potent and Convenient Once Daily Ritonavir Boosted Protease-Inhibitor for HIV-1 Infected Adults

2009 ◽  
Vol 1 ◽  
pp. CMT.S1088
Author(s):  
Clotilde Allavena ◽  
Stéphanie Trancart ◽  
Lise Cuzin
Keyword(s):  
Protease Inhibitor ◽  
Virologic Failure ◽  
High Viral Load ◽  
Virologic Response ◽  
Important Place ◽  
Once Daily ◽  
Unconjugated Hyperbilirubinemia ◽  
Gastrointestinal Tolerability ◽  
Hiv 1 ◽  
Better Than

Atazanavir is the first azapeptide protease inhibitor. As a consequence of metabolism by the Cytochrome P450 system and excretion by drug-transporters such as P-Glycoprotein, drug interactions are considerable. They can be used to improve efficacy (ritonavir boosting) but may also cause adverse effects. Efficacy of ATV/RTV has been shown to be comparable to lopinavir/ritonavir in antiretroviral naïve patients, providing even better results in patients with high viral load. Efficacy has also been demonstrated in maintenance therapy in antiretroviral-experienced patients, and in patients with previous virologic failure, providing the best virologic response when the virus harbors less than four resistance PI mutations. The gastrointestinal tolerability and the lipid profile are better than with other PIs. The major side effect is a jaundice caused by unconjugated hyperbilirubinemia that rarely leads to discontinuation. ATV/RTV simple administration as well as tolerability may be linked with better treatment adherence. ATV/RTV is simple, potent and well tolerated. Thus it takes an important place in the treatment of HIV-infected patients, preferentially in antiretroviral-naïve or moderately pretreated populations.

scholarly journals Factors Associated with Medication Adherence for People Living with Acute HIV Infection in a Tertiary Chinese Hospital in Beijing

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Xiaolan Wang ◽  
Dongmei Li ◽  
Meixia Gao ◽  
Yuefang Zhou ◽  
Caiping Guo ◽  
...  
Keyword(s):  
Medication Adherence ◽  
Public Health Issue ◽  
People Living With Hiv ◽  
Art Adherence ◽  
Hiv Diagnosis ◽  
Acute Hiv Infection ◽  
Factors Associated ◽  
Art Initiation ◽  
Acute Hiv ◽  
Hiv 1

Both the management and caregiving intervention of people living with HIV (PLWH), especially during acute HIV-1 infection, represent a public health issue and a form of social support. This current study analyzed the demographic and clinical factors associated with antiretroviral therapy (ART) adherence of PLWH from positive HIV diagnosis to ART initiation in a tertiary Chinese hospital in Beijing. A total of 200 participants diagnosed with acute HIV-1 infection were enrolled in this study. We collected demographic and clinical data by the use of a self-reported questionnaire. Bivariate and multivariate logistic regressions were used to determine associations between potential variables and outcomes. We found that medication adherence was impacted by years of ART and number of reminders (all P < 0.05 ). In addition, medication adherence was associated with viral load at 48 weeks ( P = 0.035 ). Future studies are needed to investigate effective interventions that could facilitate ART adherence.

scholarly journals Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial

2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Thomas Kakuda ◽  
Vanitha Sekar ◽  
Peter Vis ◽  
Bruce Coate ◽  
Robert Ryan ◽  
...  
Keyword(s):  
Body Weight ◽  
Population Pharmacokinetics ◽  
Clinical Experience ◽  
Response Rates ◽  
Virologic Response ◽  
Time Dependent ◽  
Pharmacokinetics And Pharmacodynamics ◽  
Lower Response ◽  
Dependent Relationship ◽  
Hiv 1

Objectives. Evaluation of pharmacokinetics and pharmacodynamics of darunavir and etravirine among HIV-1–infected, treatment-experienced adults from GRACE, by sex and race.Methods. Patients received darunavir/ritonavir 600/100mg twice daily plus other antiretrovirals, which could include etravirine 200mg twice daily. Population pharmacokinetics for darunavir and etravirine were determined over 48 weeks and relationships assessed with virologic response and safety. Rich sampling for darunavir, etravirine, and ritonavir was collected in a substudy at weeks 4, 24, and 48.Results. Pharmacokinetics were estimated in 376 patients for darunavir and 190 patients for etravirine. Median darunavir and were 60,642ng·h/mL and 3624ng/mL, respectively; and for etravirine were 4183ng · h/mL and 280ng/mL, respectively. There were no differences in darunavir or etravirine or by sex or race. Age, body weight, or use of etravirine did not affect darunavir exposure. No relationships were seen between darunavir pharmacokinetics and efficacy or safety. Patients with etravirine exposure in the lowest quartile generally had lower response rates. Rich sampling showed no time-dependent relationship for darunavir, etravirine, or ritonavir exposure over 48 weeks.Conclusions. Population pharmacokinetics showed no relevant differences in darunavir or etravirine exposure by assessed covariates. Lower etravirine exposures were associated with lower response rates.

Sign in / Sign up

Export Citation Format

Share Document